Additive manufacturing (AM), also referred to as three-dimensional printing/printed (3DP), has emerged as a transformative approach in the current design and manufacturing of various biomaterials for the restoration of damaged tissues inside the body. This advancement has greatly aided the development of customized biomedical devices including implants, prosthetics, and orthotics that are specific to the patients. In tissue engineering (TE), AM enables the fabrication of complex structures that promote desirable cellular responses in the regeneration of tissues. Since the choice of biomaterials plays a vital role in scaffold performance as well as cellular responses, meticulous material selection is essential in optimizing the functionality of scaffolds. These scaffolds often possess certain characteristics such as biodegradability, biocompatibility, biomimicry, and porous structure. To this end, polymers such as chitosan, collagen, alginate, hyaluronic acid, polyglycolic acid, polylactic acid, and polycaprolactone have been extensively investigated in the fabrication of tissue-engineered scaffolds. Furthermore, combinations of biomaterials are also utilized to further enhance the scaffolds’ performance and functionality. This review discusses the principle of AM and explores recent advancements in AM technologies in the development of TE and regenerative medicine. In addition, the applications of 3DP, polymer-based scaffolds will be highlighted.

Objective: Bigels are unique semi-solid preparations that have piqued the focus of numerous scientists owing to their significant advantages over ordinary gels. The purpose of this study was to develop and characterize innovative Bigels for applications in drug delivery by combining Hydroxypropyl methylcellulose hydrogel and sorbitan monostearate, oils like coconut and olive-based organogel. The existence of both aqueous and oil phases as bigel was revealed by microscopy. Methods: Hydrogels and organogels were prepared separately, and bigels were formed by combining hydrogel and organogel in a predetermined ratio. They were then analyzed employing various physicochemical tests i. e in vitro drug release, microscopy, and other techniques. Microscopy, viscosity measurement, mechanical analysis, and differential scanning calorimetry were used to examine the bigel's microstructures and physicochemical properties. Results: Tube inversion tests reveal that the bigel doesn’t flow under its own weight till 167 min. The microscopy suggested that the gels exhibited fiber-like structures due to the trapping of the organogel inside hydrogel molecules; this entrapment was demonstrated to be uniformly accomplished, resulting in formulation stability, and the DSC study reveals that the terbinafine is not decomposed also after formulating in bigel, and the terbinafine bigel was also found to be stable. The drug-loaded gels demonstrated effective antibacterial activity against Candida species. The formulated bigel shows initial release in 2 h and slowly release later in 4 h. The formed bigel is found to be stable after 3 mo with a pH range of 7.07±0.04, showing good spreadability and drug content was 99.99±0.75. Conclusion: Terbinafine, the drug of preference for the treatment of bacterial vaginosis, demonstrated diffusion-mediated drug release when placed into bigels. In general, the produced bigels might be employed as delivery vehicles for drugs delivered vaginally.

3D printing, a newer manufacturing technology, is gaining prominence in the pharmaceutical and healthcare sectors, particularly ENT implants. It enables the production of customized biological tissue scaffolds, portable models, and surgical training aids. The emergence of 4D printing offers the potential for enhancing ENT therapy safety and efficacy. The manuscript explores the potential of 3D printing to revolutionize pharmaceutical and clinical practice, enabling the development of personalized drug formulations, patient-centric implants, and anatomical models. This review delves into the emerging concept of “smart” biomaterials used in 4D printing, which are capable of mimicking natural tissues and responding to external stimuli. This paves the way for significant advancements in ENT tissue engineering with the potential to increase treatment safety and efficacy. This highlights the importance of healthcare staff in translating 3D printing innovations into clinical practice for successful adoption. The manuscript highlights the transformative impact of 3D printing in the pharmaceutical and healthcare industries. 3D printing and bioprinting technologies are revolutionizing ENT therapy, offering novel avenues for improved patient care and fostering advancements in the healthcare field.

Poor vascularization is one of the basic obstacles to the regeneration of functioning tissues because an oxygen diffusion process and elimination of wastes are essential in preserving the grafts. Recently, biomaterials have allowed the invention of bioinspired polymer scaffolds and replicated the natural extracellular matrix (ECM) due to the mechanical tunability of the synthetic polymers with the biological signals of natural macromolecules. The review uses a mechanistic analysis of the strategies to improve angiogenesis by using surface topography modification, bioactive peptide incorporation and pre-vascularization. Another way to achieve complex, perfusable topologies is by using more sophisticated methods of fabrication, such as electrospinning, 3D/4D bioprinting, or microfluidics. Based on in vitro and in vivo results, we determine angiogenic effectiveness by using cellular assays and animal transfers, pointing towards the translational advances in patents and clinical uses of bone, cardiac, nervous, and skin tissues. In spite of the substantial improvements, large-scale production and high demands of the regulations still exist. The future directions include the incorporation of bioinspired designs and intelligent materials, nanotechnology, and AI-based optimization into developing patient-specific and adaptive scaffolds. The following innovations herald the advent of highly effective constructs that can be used to regenerate tissue and overcome the limitations of present tissue engineering therapies through the introduction of highly effective, vascularized constructs.

Atopic dermatitis (AD) is a persistent, relapsing skin inflammatory disorder characterised by epidermal barrier dysfunction, immune system anomalies, and microbial dysbiosis. Current therapies encompass calcineurin inhibitors, topical corticosteroids, and synthetic drugs such as JAK inhibitors and biologics, which, despite their efficacy, have safety issues and constraints on prolonged use. Recently, natural bioactive compounds namely flavonoids, polyphenols, and terpenoids have garnered interest for their anti-inflammatory, antioxidant, and skin-barrier-repairing characteristics. Recent studies emphasise the incorporation of these bioactive compounds into hydrophilic/hydrophobic polymeric conjugates and nanocarrier systems to promote skin distribution, increase efficacy, and minimise systemic adverse effects. This study encapsulates traditional and innovative medicines, highlights the promise of polymer-conjugated herbal formulations, and examines recent developments in nanotechnology and delivery technologies for AD management. The increasing interest in bioactive ingredient formulations and polymeric nanocarriers indicates a favourable shift towards safer, more effective, and patient-compliant treatment methodologies. Graphical Abstract